Cytomegalovirus Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Cytomegalovirus Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The cytomegalovirus (CMV) treatment market is anticipated to register a CAGR of 6.1% during the forecast period.

As all healthcare professionals and resources were dedicated to treating coronavirus infections during the pandemic, there was a decline in demand for cytomegalovirus therapy. However, the market is expected to gain traction over the coming years owing to the resumption of treatments and the increasing prevalence of CMV in COVID-19 patients. For instance, as per the study titled "Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?" published in BMC Part of Springer Nature in March 2021, in individuals with severe COVID-19, CMV reactivation and virus-induced immune dysfunction may be overlooked as a driver of immunopathogenesis. The article further detailed that studies should be conducted to explore the possibility that CMV reactivation occasionally fuels the inflammatory response that frequently persists in patients long after SARS-CoV-2 is no longer detectable in the patient. These studies may also be pertinent for patients with long-term COVID who still experience symptoms three months after contracting the infection. The effort to diagnose CMV in COVID-19 individuals is likely to benefit the patients since antiviral medications are available that may reduce viral activity and inflammatory response. Thus, such instances suggest that the demand for cytomegalovirus in patients with COVID-19 is likely to grow, thereby having a positive impact on the market’s growth.

The rising prevalence of CMV retinitis and congenital CMV infection, extending the application range of CMV treatment, increasing initiatives for creating awareness about treatments and diagnosis of these conditions, and increasing clinical trial studies for the development of new drugs are likely to be the factors responsible for the growth of this market.

As per the Centers for Disease Control and Prevention (CDC) data updated in May 2022, in the United States, around 150 infants are born with cytomegalovirus infections every year and a few of them have long-term health issues. CMV infection in the neonate generates an attenuated interferon response associated with a similar infection in the adult. Cytomegalovirus infection and the risk of reactivation of cytomegalovirus infection have been reported during pregnancy. This can also lead to congenital CMV infection. Thus, the rising disease burden is expected to boost the penetration rate of treatments.

In addition, the increasing prevalence of viral infections among AIDS patients due to weakened immune systems is expected to drive the demand for cytomegalovirus drugs. For instance, according to the World Health Organization (WHO) updates from November 2021, HIV continues to be a major global public health issue, having claimed 36.3 million lives so far. There were an estimated 37.7 million (30.2–45.1 million) people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region. In 2020, 680,000 (480,000–1.0 million) people died from HIV-related causes, and 1.5 million (1.0–2.0 million) people acquired HIV. Since one of the most common opportunistic infections (OIs) documented in people with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is cytomegalovirus (CMV), the demand for cytomegalovirus treatment is anticipated to grow over the coming years.

Furthermore, in May 2022, Hologic, Inc. announced that the United States Food and Drug Administration (US FDA) approved its Aptima CMV Quant assay to quantify the viral load of cytomegalovirus (CMV) in patients who have had solid organ or stem cell transplants. Similarly, in October 2021, Moderna, Inc. announced the first participant had been dosed in Phase III pivotal registration study of mRNA-1647, the company’s cytomegalovirus (CMV) vaccine candidate. This study is known as CMVictory. Such developments are expected to have a positive impact on the market’s growth.

However, adverse effects and risks related to cytomegalovirus drugs may hamper the demand for the cytomegalovirus (CMV) treatment market.

Key Market TrendsStem Cell Transplantation Segment Held The Substantial Share In the Market and is Expected to Continue to Do the Same during the Forecast Period

Stem cell transplantation is poised to benefit from the inclusion of new cell types, which in turn provide substantial opportunities for companies to reinforce their market position. As a result, the number of companies involved in cell therapy development has increased tremendously over the past years. Rising funding from the government as well as private organizations to support stem cell therapy clinical trials, the introduction of effective guidelines for stem cell therapy manufacturing, and the proven effectiveness of products are some of the primary growth drivers for the market segment. In addition, declining prices of stem cell therapies are leading to an increased inclination of buyers toward this treatment.

As per the study published in July 2021, titled "CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies", CMV cell-mediated immunity assays have the potential to be used as an adjunctive test to develop an individualized management plan by identifying the patients who develop immune reconstitution. Maribavir and adoptive T cell therapy are promising new therapies for the treatment of CMV infections. CMV vaccine trials for prevention are also underway. Thus, the segment is expected to witness robust growth over the forecast period.

Moreover, in September 2022, Health Canada authorized (Notice of Compliance) Takeda's LIVTENCITY (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies and individuals who have had a solid organ transplant or a hematopoietic stem cell transplant.

Hence, the above-mentioned factors are expected to boost the market segment's growth.

North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.

North America is projected to hold the largest share of the global market throughout the forecast period. The strong regulatory framework for promoting cellular therapy development, the high adoption of treatment in the United States, and the presence of major biotechnology companies are promoting the growth of the regional market. The United States is estimated to be the leading revenue contributor in research as opposed to other countries owing to its exceptional research activities, extensive government funding, and increasing research in the area.

According to statistics published by HIV.gov in June 2021, approximately 1.2 million people in the United States have HIV (Human Immunodeficiency Virus), resulting in a total of 34,800 HIV infections with a rate of 12.6 per 100,000 people. This suggests that HIV incidences are high in the country, therefore, the demand for cytomegalovirus treatment is expected to increase over the forecast period. Additionally, in October 2021, an article published by The Borgen Project stated that in 2020, UNAIDS reported 340,000 people were living with HIV, a 55% increase from 2018’s report of 230,000 in Mexico. The program received USD 26 million in HIV treatment funding to assist "7,500 at-risk people in Mexico, Brazil, and Peru" until 2020. In Mexico, the PrEP program was open to assist up to 3,000 people with free treatments across four Mexican cities, including Puerto Vallarta, Mexico City, Merida, and Guadalajara.

Likewise, in November 2021, the first-of-its-kind therapy for post-transplant cytomegalovirus (CMV) infections was approved by the US FDA (Food and Drug Administration). Livtencity (maribavir) is intended for use in treating both adults and children who are at least 12 years old and weigh 35 kilos.

Hence, such initiatives would boost the market’s growth in the region.

Competitive Landscape

The Cytomegalovirus Treatment Market is observed to be highly competitive owing to the presence of local as well as global players. The major players include companies such as F. Hoffmann-La Roche Ltd, Fresenius Kabi Canada, Genentech, Inc., Gilead Sciences, Merck & Co., Inc, Teva Canada Limited, and Thermo Fisher Scientific. Companies are undertaking efforts to expand their customer base by promoting it to patients for usage in cytomegalovirus (CMV) infection and disease treatment.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.